Acadian Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Acadian Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$104K	Sell	3,144 -11,693	-79%	-$290K	﹤0.01%	1747
2026 Q1	$309K	Buy	+14,837	New	+$334K	﹤0.01%	1477
2025 Q4	–	Sell	-4,463	Closed	-$133K	–	2093
2025 Q3	$133K	Buy	+4,463	New	+$134K	﹤0.01%	1465
2024 Q4	–	Sell	-1,692	Closed	-$93K	–	2061
2024 Q3	$93K	Buy	+1,692	New	+$86.2K	﹤0.01%	1614
2023 Q3	–	Sell	-1,940	Closed	-$88K	–	1804
2023 Q2	$88K	Sell	1,940 -8,463	-81%	-$393K	﹤0.01%	1429
2023 Q1	$416K	Buy	10,403 +5,437	+109%	+$233K	﹤0.01%	1097
2022 Q4	$228K	Buy	4,966 +4,196	+545%	+$165K	﹤0.01%	1249
2022 Q3	$31K	Buy	+770	New	+$39.6K	﹤0.01%	1555
2021 Q3	–	Sell	-424	Closed	-$40K	–	1962
2021 Q2	$40K	Buy	+424	New	+$44.2K	﹤0.01%	1835
2021 Q1	–	Sell	-364	Closed	-$50K	–	2279
2020 Q4	$50K	Buy	+364	New	+$43.2K	﹤0.01%	1933

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Acadian Asset Management's RARE Position: Q2 2026 in Review

Acadian Asset Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 79% in Q2 2026, selling an estimated $290K and leaving 3,144 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #1747.

Acadian Asset Management first reported a position in RARE in Q4 2020 and has held it in 10 quarters since. The position peaked at $416K in Q1 2023. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Acadian Asset Management held 3,144 shares of Ultragenyx Pharmaceutical worth $104K as of Q2 2026.
Acadian Asset Management sold 11,693 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $290K.
Ultragenyx Pharmaceutical made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1747 holding.
Acadian Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and has held it in 10 quarters since.
Acadian Asset Management's Ultragenyx Pharmaceutical position peaked at $416K in Q1 2023.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.